Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Link opens in a new tab
Search content at UTMB Health Research Expert Profiles
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Targeting complement system to treat myasthenia gravis
Ruksana Huda
, Erdem Tüzün
, Premkumar Christadoss
Microbiology And Immunology
Research output
:
Contribution to journal
›
Article
›
peer-review
29
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Targeting complement system to treat myasthenia gravis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Myasthenia Gravis
100%
Complement System
100%
Experimental Autoimmune
80%
Complement Inhibitors
60%
Neuromuscular Junction
40%
Complement Pathway
40%
Autoimmune Disease
20%
Protective Immunity
20%
Treatment Strategy
20%
Clinical Trials
20%
Therapeutic Approaches
20%
Small Interfering RNA (siRNA)
20%
Autoantibodies
20%
Muscle Weakness
20%
Immunosuppression
20%
Experimental Autoimmune Myasthenia Gravis
20%
Acetylcholine Receptor Antibody
20%
Antibody-based
20%
Membrane Attack Complex
20%
Decay Accelerating Factor
20%
Anti-C1q
20%
Complement C3
20%
Immunoglobulin Isotypes
20%
C5 Inhibitor
20%
Eculizumab
20%
Complement Factors
20%
Antibody-based Therapeutics
20%
Immunology and Microbiology
Myasthenia gravis
100%
Complement System
100%
Autoimmunity
80%
Complement Inhibitor
60%
Neuromuscular Junction
40%
Cytokine
20%
Autoantibodies
20%
Autoimmune Disease
20%
Immunosuppression
20%
Immunosuppressive Drug
20%
Experimental Autoimmune Myasthenia Gravis
20%
Complement Membrane Attack Complex
20%
Decay-Accelerating Factor
20%
Complement Component C1q
20%
Complement Component 3
20%
Immunoglobulin Class
20%
Complement Factor
20%
Eculizumab
20%
Peptides
20%
Muscle
20%
Ribonucleic Acid
20%
Susceptibility
20%
Pharmacology, Toxicology and Pharmaceutical Science
Myasthenia gravis
100%
Complement Inhibitor
60%
Clinical Trial
20%
Autoimmune Disease
20%
Receptor
20%
Cytokine
20%
Autoantibodies
20%
Small Interfering RNA
20%
Immunosuppressive Agent
20%
Complement Membrane Attack Complex
20%
Complement Component C3
20%
Complement Factor
20%
Muscle Weakness
20%
Experimental Autoimmune Myasthenia Gravis
20%
Complement Component C1q
20%
Immunoglobulin Class
20%
Eculizumab
20%
Decay Accelerating Factor
20%
Side Effect
20%
Neuroscience
Myasthenia gravis
100%
Complement System
100%
Neuromuscular Junction
33%
Autoantibodies
16%
Small Interfering RNA
16%
Immunosuppression
16%
Immunosuppressive Drug
16%
Complement Membrane Attack Complex
16%
Autoimmune Disease
16%
Complement Component C3
16%
Decay Accelerating Factor
16%
Complement Factor
16%
Immunoglobulin Class
16%
Complement Component C1q
16%
Eculizumab
16%
Receptor
16%
Side Effect
16%
Cytokine
16%
Biochemistry, Genetics and Molecular Biology
Autoimmunity
100%
Complement System
100%
Intravenous Immunoglobulin
16%
Cytokine
16%
Clinical Trial
16%
Complement Membrane Attack Complex
16%
Autoantibodies
16%
Complement Component 3
16%
Decay-Accelerating Factor
16%
Deficiency
16%
Small Interfering RNA
16%